Hepatocellular Adenoma Treatment & Management
- Author: Bradford A Whitmer, DO; Chief Editor: BS Anand, MD more...
Patients should stop using oral contraceptives or anabolic steroids. This allows for regression in the size of the majority of the tumors. Complete resolution is atypical. The risk of malignant transformation remains even after the contraceptive or steroid use has been discontinued.
Symptomatic tumors should be resected, regardless of size.
Pregnancy should be avoided because of the risk of growth and rupture but is not an absolute contraindication. There are no consensus guidelines. Surgical resection may be the best option in patients with hepatocellular adenomas who desire to become pregnant. Large incidental HCAs found during pregnancy may be considered for resection during the second trimester, when the risk is lowest. Asymptomatic HCAs smaller than 5 centimeters may be managed with close monitoring. MRI seems to be preferred given the lack of radiation, but cost effectiveness remains to be studied. Ruptured hepatocellular adenomas during pregnancy should be managed with resuscitation and resection.
Yearly ultrasound imaging and an assessment of serum AFP levels is a consideration in all patients with hepatocellular adenomas, especially those with multiple lesions or single lesions greater than 5 cm in diameter who do not undergo surgical resection. However, there is little evidence to support this approach.
Immediate abdominal imaging is required for patients with hepatocellular adenomas who present with new or worsened abdominal pain or signs of hemodynamic instability.
Emergency hepatic arteriography with embolization should be considered to control bleeding in high-risk surgical candidates.
Transarterial embolization has been used to electively reduce the tumor mass of a large HCA, but studies are limited in using it as an elective treatment for unruptured HCA.[51, 52]
Due to the increased risk of spontaneous life-threatening hemorrhage and the possible malignant transformation associated with larger-size tumors or in patients with GSD, elective surgical resection is considered for all lesions greater than 5 cm in diameter. Elective resection should be undertaken only after a reasonable period of observation if OCPs have been discontinued only recently. However, several authorities recommend that all adenomas should be resected regardless of size due to rare cases of malignant transformation after adenomas have decreased in size or disappeared after discontinuation of OCPs.
In a multicenter study of 124 patients, Deneve et al reported that tumors that were more likely to rupture were larger tumors and in women with recent hormone use. The investigators recommended surgical resection when HCAs approached 4 cm in size or if hormonal therapy was required.
All patients with significantly elevated AFP levels should undergo resection of the tumor regardless of size.
The majority of tumors can be resected locally or with segmental partial lobectomy. Elective resection carries approximately 13% morbidity. Mortality is rare. Complication rates associated with emergency surgery are higher, including a mortality rate of approximately 5-8%.
Laparoscopic resection can be used in patients who have small tumors within the anterolateral liver segments and for pedunculated tumors.
Cho et al reported their experience with the management and outcomes of 41 patients with hepatocellular adenomas treated at the University of Pittsburgh between 1988 and 2007. The investigators reported that surgical resection was preferable to observation if patients comorbidities and anatomical location are acceptable due to risks of hemorrhage (29%) and malignancy (5%).
In rare patients with multiple adenomas or glycogen storage disease, liver transplantation may be the only intervention that may remove all lesions and cure the underlying metabolic defect.[11, 54] Liver transplantation has also been successfully performed for spontaneous intrapartum rupture of an hepatocellular adenoma.
Radiofrequency (RF) ablation can be used effectively in the treatment of hepatocellular adenoma. However, multiple sessions are often required, and signs of residual adenoma might persist in some patients despite repetitive treatment. RF ablation might be especially beneficial in cases not amenable to surgery or in patients who would require major hepatic resection. Cases not amenable to surgery would include centrally located lesions or multiple HCAs in both lobes of the liver.
Edmonson HA. Tumors of the liver and biliary tract. Fascicle 25. Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology; 1958.
Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med. 1976 Feb 26. 294(9):470-2. [Medline].
Baum JK, Bookstein JJ, Holtz F. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973 Oct 27. 2(7835):926-9. [Medline].
Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology. 1977 Aug. DA - 19770825(2):386-94. [Medline].
Rooks JB, Ory HW, Ishak KG. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA. 1979 Aug 17. 242(7):644-8. [Medline].
Cherqui D, Rahmouni A, Charlotte F, et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology. 1995 Dec. 22(6):1674-81. [Medline].
Edmonson HA, Reynolds TB, Henderson B, et al. Regression of liver cell adenomas associated with oral contraceptives. Ann Int Med. 1977. 86(2):180-182.
Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr. 1997 Mar. 24(3):276-9. [Medline].
Volmar KE, Burchette JL, Creager AJ. Hepatic adenomatosis in glycogen storage disease type Ia: report of a case with unusual histology. Arch Pathol Lab Med. 2003 Oct. 127(10):e402-5. [Medline].
Grazioli L, Federle MP, Ichikawa T, et al. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology. 2000 Aug. 216(2):395-402. [Medline].
Arsenault TM, Johnson CD, Gorman B, Burgart LJ. Hepatic adenomatosis. Mayo Clin Proc. 1996 May. 71(5):478-80. [Medline].
Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg. 2010. 27(1):39-45. [Medline].
Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009 Aug. 50(2):481-9. [Medline].
Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007 Sep. 46(3):740-8. [Medline].
Van der Borght S, Libbrecht L, Katoonizadeh A, et al. Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology. 2007 Dec. 51(6):855-6. [Medline].
Bioulac-Sage P, Taouji S, Possenti L, Balabaud C. Hepatocellular adenoma subtypes: the impact of overweight and obesity. Liver Int. 2012 Sep. 32(8):1217-21. [Medline].
Masood S, West AB, Barwick KW. Expression of steroid hormone receptors in benign hepatic tumors. An immunocytochemical study. Arch Pathol Lab Med. 1992 Dec. 116(12):1355-9. [Medline].
Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol. 2008 Jan. 48(1):163-70. [Medline].
Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol. 2007 May 21. 13(19):2649-54. [Medline].
Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. Radiology. 2011 Mar. 258(3):673-93. [Medline].
Reznik Y, Dao T, Coutant R, et al. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab. 2004 Mar. 89(3):1476-80. [Medline].
Lin H, van den Esschert J, Liu C, van Gulik TM. Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol. 2011 Jan. 26(1):28-35. [Medline].
van Aalten SM, de Man RA, IJzermans JN, Terkivatan T. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg. 2012 Jul. 99(7):911-6. [Medline].
Cho SW, Marsh JW, Steel J, et al. Surgical management of hepatocellular adenoma: take it or leave it?. Ann Surg Oncol. 2008 Oct. 15(10):2795-803. [Medline].
Deneve JL, Pawlik TM, Cunningham S, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol. 2009 Mar. 16(3):640-8. [Medline].
Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009 Nov. 137(5):1698-705. [Medline].
Toso C, Majno P, Andres A, et al. Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors. World J Gastroenterol. 2005 Sep 28. 11(36):5691-5. [Medline].
Stoot JH, Coelen RJ, De Jong MC, Dejong CH. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford). 2010 Oct. 12(8):509-22. [Medline]. [Full Text].
Ryan IP, Havel RJ, Laros RK Jr. Three consecutive pregnancies in a patient with glycogen storage disease type IA (von Gierke's disease). Am J Obstet Gynecol. 1994 Jun. 170(6):1687-90; discussion 1690-1. [Medline].
van Aalten SM, Thomeer MG, Terkivatan T, et al. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology. 2011 Oct. 261(1):172-81. [Medline].
Katabathina VS, Menias CO, Shanbhogue AK, Jagirdar J, Paspulati RM, Prasad SR. Genetics and imaging of hepatocellular adenomas: 2011 update. Radiographics. 2011 Oct. 31(6):1529-43. [Medline].
van den Esschert JW, van Gulik TM, Phoa SS. Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma. Dig Surg. 2010. 27(1):46-55. [Medline].
Piscaglia F, Lencioni R, Sagrini E, et al. Characterization of focal liver lesions with contrast-enhanced ultrasound. Ultrasound Med Biol. 2010 Apr. 36(4):531-50. [Medline].
Dietrich CF, Schuessler G, Trojan J, Fellbaum C, Ignee A. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol. 2005 Aug. 78(932):704-7. [Medline].
Kim TK, Jang HJ, Burns PN, Murphy-Lavallee J, Wilson SR. Focal nodular hyperplasia and hepatic adenoma: differentiation with low-mechanical-index contrast-enhanced sonography. AJR Am J Roentgenol. 2008 Jan. 190(1):58-66. [Medline].
Laumonier H, Bioulac-Sage P, Laurent C, et al. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology. 2008 Sep. 48(3):808-18. [Medline].
Hechtman JF, Raoufi M, Fiel MI, et al. Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear ß-catenin and glutamine synthetase positivity: case report and review of the literature. Am J Surg Pathol. 2011 Jun. 35(6):927-32. [Medline].
Joseph NM, Ferrell LD, Jain D, et al. Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma. Mod Pathol. 2014 Jan. 27(1):62-72. [Medline].
Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006 Mar. 43(3):515-24. [Medline].
Tretiakova MS, Hart J, Shabani-Rad MT, Zhang J, Gao ZH. Distinction of hepatocellular adenoma from hepatocellular carcinoma with and without cirrhosis using E-cadherin and matrix metalloproteinase immunohistochemistry. Mod Pathol. 2009 Aug. 22(8):1113-20. [Medline].
Wang HL, Anatelli F, Zhai QJ, et al. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med. 2008 Nov. 132(11):1723-8. [Medline].
Tatrai P, Somoracz A, Batmunkh E, et al. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions. Am J Surg Pathol. 2009 Jun. 33(6):874-85. [Medline].
Ahmad I, Iyer A, Marginean CE, et al. Diagnostic use of cytokeratins, CD34, and neuronal cell adhesion molecule staining in focal nodular hyperplasia and hepatic adenoma. Hum Pathol. 2009 May. 40(5):726-34. [Medline].
Bioulac-Sage P, Cubel G, Taouji S, et al. Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am J Surg Pathol. 2012 Nov. 36(11):1691-9. [Medline].
Hussain SM, van den Bos IC, Dwarkasing RS, Kuiper JW, den Hollander J. Hepatocellular adenoma: findings at state-of-the-art magnetic resonance imaging, ultrasound, computed tomography and pathologic analysis. Eur Radiol. 2006 Sep. 16(9):1873-86. [Medline].
Ishak KG. Benign tumors and pseudotumors of the liver. Appl Pathol. 1988. 6(2):82-104. [Medline].
Bisceglia M, Gatta A, Tomezzoli A, Donataccio M. Multiple spontaneous liver cell adenomas of different types (liver adenomatosis). Adv Anat Pathol. 2009 May. 16(3):172-9. [Medline].
Geller S, Petrovic L. Benign tumors and tumor-like conditions. Biopsy Interpretation of the Liver. 3rd ed. Philadelphia, Pa: Williams and Wilkins.; 2003. 281-304.
Gyorffy EJ, Bredfeldt JE, Black WC. Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann Intern Med. 1989 Mar 15. 110(6):489-90. [Medline].
Erdogan D, van Delden OM, Busch OR, Gouma DJ, van Gulik TM. Selective transcatheter arterial embolization for treatment of bleeding complications or reduction of tumor mass of hepatocellular adenomas. Cardiovasc Intervent Radiol. 2007 Nov-Dec. 30(6):1252-8. [Medline].
Stoot JH, van Roosmalen J, Terpstra OT, Schaapherder AF. Life-threatening hemorrhage from adenomas in the liver during pregnancy. Dig Surg. 2006. 23(3):155. [Medline].
Terkivatan T, de Wilt JH, de Man RA, et al. Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg. 2001 Sep. 136(9):1033-8. [Medline].
Selby R, Starzl TE, Ynis E, et al. Liver transplantation for type 1 and type glycogen storage disease. Eur J Pediatr. 1993. 152:S71-76.
Santambrogio R, Marconi AM, Ceretti AP, et al. Liver transplantation for spontaneous intrapartum rupture of a hepatic adenoma. Obstet Gynecol. 2009 Feb. 113(2 pt 2):508-10. [Medline].
van Vledder MG, van Aalten SM, Terkivatan T, et al. Safety and efficacy of radiofrequency ablation for hepatocellular adenoma. J Vasc Interv Radiol. 2011 Jun. 22(6):787-93. [Medline].
Bioulac-Sage P, Laumonier H, Cubel G, Rossi JZ, Balabaud C. Hepatic resection for inflammatory hepatocellular adenomas: pathological identification of micronodules expressing inflammatory proteins. Liver Int. 2010 Jan. 30(1):149-54. [Medline].
Cai YR, Gong L, Teng XY, et al. Clonality and allelotype analyses of focal nodular hyperplasia compared with hepatocellular adenoma and carcinoma. World J Gastroenterol. 2009 Oct 7. 15(37):4695-708. [Medline]. [Full Text].
Curvo-Semedo L, Brito JB, Seco MF, Costa JF, Marques CB, Caseiro-Alves F. The hypointense liver lesion on T2-weighted MR images and what it means. Radiographics. 2010 Jan. 30(1):e38. [Medline].
Jang HJ, Yu H, Kim TK. Contrast-enhanced ultrasound in the detection and characterization of liver tumors. Cancer Imaging. 2009 Nov 6. 9:96-103. [Medline].
van der Sluis FJ, Bosch JL, Terkivatan T, et al. Hepatocellular adenoma: cost-effectiveness of different treatment strategies. Radiology. 2009 Sep. 252(3):737-46. [Medline].
Brunel T, Guibal A, Boularan C, et al. Focal nodular hyperplasia and hepatocellular adenoma: The value of shear wave elastography for differential diagnosis. Eur J Radiol. 2015 Aug 3 [Epub ahead of print]. [Medline].
Mounajjed T, Yasir S, Aleff PA, Torbenson MS. Pigmented hepatocellular adenomas have a high risk of atypia and malignancy. Mod Pathol. 2015 Sep. 28(9):1265-74. [Medline].